Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon

详细信息    查看全文

• 作者：Lucio Boglione ; ^{lucio.boglione@unito.it} ; Jessica Cusato ; Giuseppe Cariti ; Giovanni Di Perri ; Antonio D'Avolio
• 关键词：Hepatitis B treatment ; PEG-IFN ; HBV genotype ; qHBsAg ; HBeAg-negative
• 刊名：Antiviral Research
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：136
• 期：Complete
• 页码：32-36
• 全文大小：514 K
• 卷排序：136

文摘

The role of HBsAg decline during PEG-IFN therapy in E genotype has not been demonstrated. Sustained response to PEG-IFN in E genotype was poor. Combining the HBsAg and HBV-DNA decline at 12 weeks we can identify patients without any chance of response. The stopping rule at 12 weeks is useful also in patients with E genotype.